NVO This is time to buy!All in! (Just my personal decision no FA)
Community discussions
NVO This is time to buy!All in! (Just my personal decision no FA)
NVO more holders need to get shaken out before this bottoms. Anyone bullish on earnings around the corner?
NOVOBC still is so painfull, anyone now why everyon is selling? I udnerstand forecast and competition might not been that bright, but the fundamental and financials are so good.I'm bleeding like hell on this one haha
NOVO_B I wouldn't be surprised if the price reaches its lowest level at the DK market close, and bounces in the evening hours. Then rise less from the 10xbull certificates. So only buy at the close, or wait until Monday.
NVO ok bought 1000 share at 48.7. This shyt need to start moving up
NVO holding this and Duolingo is painful
NVO this stock is a disgraceNVO If the price can stand, not go through 48$ bullish reversal plan will still be intact
NVO 🔬 Fundamental Analysis (FA): Company Health & Value 💪Novo Nordisk = The pharma powerhouse behind blockbuster drugs Ozempic & Wegovy 💊🔥 — leaders in the booming obesity & diabetes market.
Key Financials:
💹 Revenue: $311B TTM — up strongly year-over-year.
💰 Net Income: $111B → solid 36% profit margin.
🧮 ROE: 79% — extreme efficiency turning equity into profit.
💳 Debt: $99B → stable, not a red flag.
💧 Free Cash Flow: Expected to rise steadily.
📊 Explanation:
High profit margins + explosive ROE = strong operational dominance.
Even though debt exists, it’s manageable given the massive cash generation.
At 12x PE and 5.3x sales, the stock trades well below its historical premium — typically a bullish sign for long-term investors.
⚖️ Liquidity Note: Current ratio 0.78 = slightly tight (less current assets vs liabilities), but not alarming for a cash-flow-rich company like NVO.
🧠 Interpretation: Financials confirm NVO is undervalued — the fundamentals support a bullish reaccumulation setup, not a decline phase. 📈
⚡ Catalyst & News-Driven Analysis: Sparks on the Horizon 🔥
October’s been action-packed! 🗞️
💣 Breaking: Novo launched a $9B bid for Metsera, beating Pfizer’s $6.5B.
👉 Why it matters: Metsera owns next-gen weight-loss tech — this could extend NVO’s GLP-1 (Ozempic/Wegovy) leadership for years.
💹 If the deal closes → expect a short-term rally of +5–10%.
📅 Upcoming Events:
🧾 Q3 Earnings (Nov 5): Forecasting +20% sales growth on obesity drug demand.
🗳️ EGM (Nov 14): Board reshuffle = potential strategic realignment.
🧬 R&D Buzz: Oral semaglutide trials expanding into Alzheimer’s field.
🧯 Patent protection until 2032 = long-term revenue security.
📊 Explanation:
Markets price in future catalysts, not just current numbers — so the Metsera bid and earnings outlook are key short-term momentum triggers. The news cycle is bullish, but price hasn’t yet reacted — that’s where traders catch early alpha. ⚡
NVO ⚙️ Plan OverviewThe bearish setup on NVO is crystal clear — price is rejecting hard from the 200 EMA, confirming strong downside momentum.
The bulls got trapped near resistance, and now the bears are taking full control with high-pressure downside flows.
🧭 Thief Vision:
When EMA acts as a wall, the market starts bleeding quietly before the real panic drop — and that’s where we prepare our Thief layers!
💣 Entry Plan – “Thief Layering Strategy”
We don’t chase, we trap!
Use layered sell limit orders to scale in like a pro thief waiting for the vault door to open.
💰 Sell Limit Layers:
53.00
52.00
51.00
(You can add more layers depending on your risk appetite & style.)
🛑 Stop Loss (SL)
🎯 SL @ 320
⚠️ Note (Thief OG’s Reminder):
Dear Ladies & Gentlemen — I’m not recommending you use my SL.
It’s your money, your rules. Manage risk like a pro and exit smart, not emotional.
🎯 Profit Target (TP)
Target the strong support & oversold zone near 44.00 — that’s where the market trap is waiting to release early bears and trap late shorts.
💎 TP @ 44.00
⚠️ Note:
This is a Thief-style game plan. Take profit wisely, and remember — the first rule of Thief Club: take money, then disappear quietly!
🌐 Correlated Pairs & Market Watchlist
Keep an eye on correlated or sympathy assets that often mirror or inversely react to
NVO’s movement:💊 LLY (Eli Lilly) — Similar pharma sector behavior; tracks institutional flows.
🧬 PFE (Pfizer) — High-cap health stock; can influence sector sentiment.
💹 SPY (S&P 500 ETF) — Broader market sentiment impacts NVO’s volatility.
💵 USDJPY / DXY — Dollar strength can affect foreign flow into U.S. pharma.
🩺 XLV (Health Sector ETF) — Gives overall direction for healthcare momentum.
📈 Watch these tickers — sector rotation or USD flows often hint at NVO continuation or pullback phases.
